IMed Group, a leading provider of specialist services to the global medical and health technology sector, has appointed Parminder Kalle as its new Chief Commercial Officer (CCO), marking a significant step in the company’s strategy to expand its international footprint.
Parminder joins the organisation with more than 20 years of experience across medical devices, in vitro diagnostics (IVDs), Pharma and digital health, bringing a mix of technical expertise and commercial leadership.
In his new role, Parminder will spearhead IMed Group’s business development and global strategic growth initiatives. His remit includes accelerating the company’s international expansion, deepening strategic partnerships and strengthening the integration of IMed Group’s quality, regulatory and clinical services.
His overarching goal is to position the Group as a trusted global partner delivering not only compliance but meaningful value for clients through innovation, insight and operational agility.
As Chief Commercial Officer, Parminder will lead all commercial operations across IMed Group’s three core service areas: quality, regulatory and clinical services. His leadership approach blends technical excellence with agile commercial strategy, drawing on a detailed understanding of regulatory environments, market access pathways and reimbursement frameworks.
At IMed, he aims to ensure that clients can successfully navigate complex regulatory and quality requirements while turning compliance into a strategic advantage.
“IMed Group is entering an exciting phase of evolution,” said Parminder. “Our strength lies in combining deep regulatory expertise with commercial strategy. My focus is on driving growth through meaningful partnerships and helping our clients adapt quickly to industry change, turning compliance and quality into a platform for long-term success.”
His appointment forms part of IMed Group’s wider strategy to scale its global operations and enhance its end-to-end service offering across the Medtech sector. CEO Leeanne Baker welcomed the appointment, noting the value of Parminder’s broad experience.
“Parm brings a rare combination of technical expertise, commercial acumen and international experience,” she said. “His appointment strengthens our ability to deliver innovative, client-focused solutions across the global life sciences sector. We are confident that his leadership will enable IMed Group to grow further while continuing to provide outstanding support to our clients.”
Founded in 2012, IMed Group provides a comprehensive range of expert services to medical device and in vitro medical device manufacturers, supporting innovation and helping improve patient care worldwide.
Its consultancy team offers regulatory guidance from concept and design through clinical studies and post-market surveillance, drawing on more than 70 years of combined hands-on experience to ensure that devices are launched and maintained in full compliance across the UK, EU and international markets.
